Applications of Fmoc-(S)-3-Amino-4-(2-Cyano-Phenyl)-Butyric Acid in Industrial Manufacturing

As the original manufacturer, we supply Fmoc-(S)-3-Amino-4-(2-Cyano-Phenyl)-Butyric Acid for advanced peptide synthesis, supporting specialized pharmaceutical and life science applications. Our technical team partners directly with industrial clients globally to meet exacting downstream needs, from regulated drug development to the latest research-based APIs.

1. Active Pharmaceutical Ingredient (API) Peptide Synthesis

API manufacturers use our raw material as a key building block for constructing pharmacologically active peptides, particularly those requiring complex, nonstandard amino acids. It enters solid-phase peptide synthesis (SPPS) cycles, supporting the assembly of bioactive sequences under strict compliance with regulatory standards. Quality control requires precise adjustment of the coupling ratio depending on each target molecule and regulatory expectations for purity, especially in the context of new peptide drug entities under clinical development or generic peptide API production.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs for peptides
• US FDA 21 CFR Part 210/211 cGMP regulations
• ICH Q3A/Q3B guidelines for impurity control

Typical usage ratio

• Templated at 1 molar equivalent per coupling step; variation from 0.95–1.1 based on target peptide length and cycle optimization

Downstream process integration

• Fmoc-protected amino acid is loaded onto a resin during the initial phase of automated or batchwise SPPS, with cleavage and deprotection dictated by the peptide synthesis protocol and subsequent chromatographic purification

Final product types

• Peptide API bulk intermediates
• Finished injectable and oral peptide pharmaceuticals
• Preclinical drug candidates for regulatory submission

2. Custom Peptide Manufacturing for Antibody-Drug Conjugates (ADC)

Contract manufacturing organizations (CMOs) and biopharma research divisions depend on this material for preparing highly defined peptide linkers for ADC payloads. These linkers require introduction of precise side-chain functionalities such as cyano groups for subsequent conjugation chemistry and stability profiling. Process engineers fine-tune the ratio to ensure linker uniformity and batch-to-batch reproducibility for clinical-grade synthesis lots.

Industry compliance standards

• USP General Chapter <823> for radiopharmaceuticals (where applicable)
• ISO 13485 for medical device-related biologics
• FDA and EMA guideline on the quality of monoclonal antibodies and antibody-derived products

Typical usage ratio

• Range of 0.9–1.05 molar equivalents per coupling, with optimization depending on linker sequence complexity and payload compatibility

Downstream process integration

• Introduced at the protected amino acid coupling stage in solid-phase peptide linker synthesis; final deprotection and conjugation takes place prior to payload attachment and purification

Final product types

• Synthetic peptide linkers for ADCs
• Peptide-functionalized cytotoxic drug intermediates
• Custom research-grade ADCs for proof-of-concept and process validation

3. Research Reagent Peptide Synthesis for Proteomics

Core laboratories in biotechnology, proteomics, and university research institutions order this advanced amino acid for synthesizing labeled or modified peptide standards. It is integral to producing tools for quantitative mass spectrometry, with process control focusing on sequence integrity for assay calibration and diagnostic kit development. Batch records require documentation of actual equivalents used due to varying sequence lengths and application-specific purity requirements.

Industry compliance standards

• ISO/IEC 17025 accreditation for analytical laboratories
• GLP (Good Laboratory Practice) where applicable for preclinical research
• Institutional review and material traceability guidelines

Typical usage ratio

• Standard input of 0.95–1.05 equivalents per targeted amino acid insertion, with adjustments based on resin loading efficiency or for isotopically labeled batches

Downstream process integration

• Functionalized onto resin during automated peptide synthesizer cycles, then cleaved, deprotected, and purified using preparative HPLC or UPLC prior to labeling or freeze-drying

Final product types

• Peptide internal standards for LC-MS or MALDI-MS
• Stable isotope-labeled peptide markers
• Custom peptide controls for assay development

4. Peptide-Based Diagnostic Kit Component Production

Manufacturers of in vitro diagnostic (IVD) kits use this specialty amino acid for the synthesis of selective peptide sequences that serve as antigenic probes or calibrator controls. Compliance demands tight control over batch-to-batch identity and purity, as false negatives/positives in diagnostic settings carry regulatory consequences. Usage ratios are determined according to peptide probe chain length and multiplexing requirements of end kits.

Industry compliance standards

• IVD Medical Device Regulations (EU 2017/746)
• ISO 13485:2016 for medical device and diagnostic kit quality management
• FDA 21 CFR Part 820 (Quality System Regulation) for IVD

Typical usage ratio

• Typically set at a 1:1 molar ratio per coupling event; can range from 0.9–1.1 to optimize for chain elongation and solvency limitations

Downstream process integration

• Incorporated at initial or mid-point peptide coupling stages during batch or microwave-assisted SPPS, followed by selective deprotection and lyophilization prior to final formulation into diagnostic kits

Final product types

• Peptide-based antigens for ELISA and immunoassays
• Reference and calibration standards in multiplexed diagnostic arrays
• Control peptides for quality assurance in rapid diagnostic test cassettes